In these contexts, Omomyc showed safety and efficacy both upon intranasal and intravenous administration and induced shutdown of MYC transcriptional programs and reprogramming of the tumor microenvironment18, recapitulating several key features of expression of the Omomyc transgene15,16. The gene discussed is MYC; the disease is neoplasm.